Pyrrolo [2, 3-d] pyrimidine-6-thioketone derivative and application thereof in medicine
By developing new compounds with good pharmacopoeia and bioavailability, the problems of toxic side effects and insufficient therapeutic effects of existing sGC modulators or agonists in the treatment of related diseases have been solved, and more efficient and safe therapeutic effects have been achieved.
Patent Information
- Application Number
- CN202410689077.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-12-12
- Filing Date
- 2024-05-30
- Publication Date
- 2024-12-03
AI Technical Summary
Existing sGC modulators or agonists have high toxic side effects when treating related diseases, and their therapeutic effects are limited, making it difficult to improve bioavailability and safety.
Develop a novel structured compound of formula (I) and its stereoisomers, deuterated agents, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or co-crystals, with good pharmacopoietic properties and bioavailability and improve its oral performance and safety through specific preparation methods.
The higher therapeutic effect and lower toxic side effects of the compounds in the treatment of sGC-related diseases are achieved, and bioavailability and safety are improved. It is suitable for the treatment of cardiovascular, renal and respiratory diseases.
Smart Images

Figure CN119060056A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medicine, and specifically relates to a compound represented by formula (I) or a stereoisomer, a tautomer, a deuterated substance, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a cocrystal thereof, and use thereof in the preparation of a drug for treating diseases associated with sGC. Background Art
[0002] Nitric oxide (NO) signaling has pleiotropic effects in biology and plays a key role in cardiovascular homeostasis. NO secretion is increased under the influence of mediators such as norepinephrine (NA), angiotensin, adenosine triphosphate or bradykinin. NO synthesis is also affected by many physical stimuli (Int. J. Mol. Sci. 2021, 22, 6029; Molecules 2021, 26, 3418).
[0003] The intracellular mechanism of action of NO is mainly through stimulating the activity of soluble guanylate cyclase (sGC). sGC is a heme-containing enzyme that can increase the level of cyclic 3'-5'-guanosine monophosphate (cGMP) in smooth muscle and cause vasodilation (Nat. Rev. Cardiol. 2018, 15, 292–316). The NO / sGC / cGMP regulatory pathway plays an important role in the homeostasis of the cardiovascular and respiratory systems and organs (such as the kidneys, brain, and liver). In addition to smooth muscle cells, cGMP also affects the function of fibroblasts, cardiomyocytes, platelets, neurons, and immune cells, regulating fibrosis, inflammatory responses, and neurotransmission processes (Molecules 2023, 28, 861).
[0004] sGC regulators and sGC agonists are a class of drugs that can stimulate the formation of cGMP. These drugs provide tools for studying the regulation mechanism of sGC and its role in pathological mechanisms. The development of sGC regulators or agonists makes it possible for drugs to directly target diseased blood vessels, myocardium, kidneys and other organs (Molecules 2023, 28, 861). Riociguat is the first sGC agonist to be marketed. In 2013, Riociguat was approved for two indications: pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (TEPH) (J. Med. Chem. 2017, 60, 5146-5161). In the 12-week multicenter, double-blind, randomized, placebo-controlled, pivotal PATENT-1 study, the most common (≥3%) AEs in the riociguat treatment group compared with placebo were headache (27% vs. 18%), dyspepsia / gastritis (21% vs. 8%), dizziness (20% vs. 13%), nausea (14% vs. 11%), diarrhea (12% vs. 8%), hypotension (10% vs. 4%), vomiting (10% vs. 7%), anemia (7% vs. 2%), gastroesophageal reflux disease (5% vs. 2%), and constipation (5% vs. 1%). The development of new sGC modulators or agonists to improve the therapeutic effect or reduce toxic side effects has good application prospects. Summary of the invention
[0005] The object of the present invention is to provide a novel compound of the general formula (I) or a stereoisomer, deuterated product, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, as well as an intermediate and a preparation method thereof, and use thereof in the preparation of a drug for treating diseases associated with sGC.
[0006] The compound of the invention has good pharmacokinetic properties and bioavailability, oral properties and good safety.
[0007] The present invention provides a compound represented by general formula (I) or a stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof.
[0008]
[0009] In some embodiments, the compound represented by general formula (I) is selected from the compound represented by general formula (II),
[0010]
[0011] In some embodiments, Z is selected from CH or N;
[0012] In some embodiments, A is selected from C 3-12Carbocyclic group or 4-12 membered heterocyclic group;
[0013] In some embodiments, A is selected from C 3-11 Cycloalkyl, 4- to 11-membered heterocycloalkyl, C 6-10 Aryl or 5-10 membered heteroaryl;
[0014] In some embodiments, A is selected from C 3-6 Cycloalkyl, 4- to 6-membered heterocycloalkyl, C 6-10 Aryl or 5-10 membered heteroaryl;
[0015] In some embodiments, A is selected from the group consisting of a Substituted as follows: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, phenyl, pyrrolyl, thienyl, furanyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl;
[0016] In some embodiments, A is selected from the group consisting of a Substituted groups include phenyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl, and pyridazinyl;
[0017] In some embodiments, A is selected from the group consisting of a The following groups substituted: phenyl, thiazolyl;
[0018] In some embodiments, R 1 Selected from -M-(CR 1a R 1b ) r -(CR 1c R 1d ) s -COOH;
[0019] In some embodiments, R 1 Selected from
[0020] In some embodiments, R 1 Selected from
[0021] In some embodiments, M is selected from a bond, C 3-12 A carbocyclic group or a 4-12 membered heterocyclic group, wherein the carbocyclic group or the heterocyclic group is optionally substituted by 1 to 4 R m replace;
[0022] In some embodiments, M is selected from a bond, C 3-11Cycloalkyl, 4- to 11-membered heterocycloalkyl, C 6-10 aryl or 5-10 membered heteroaryl, the cycloalkyl, heterocycloalkyl, aryl, heteroaryl is optionally substituted by 1 to 4 R m replace;
[0023] In some embodiments, M is selected from a bond, C 3-6 Cycloalkyl, 4- to 6-membered heterocycloalkyl, C 6-10 aryl or 5-10 membered heteroaryl, the cycloalkyl, heterocycloalkyl, aryl, heteroaryl is optionally substituted by 1 to 4 R m replace;
[0024] In some embodiments, M is selected from a bond or optionally substituted by 1 to 4 R m Substituted groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, phenyl, pyrrolyl, thienyl, furanyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl;
[0025] In some embodiments, R 2 Selected from C 1-6 Alkyl or -C 1-6 Alkylene-Q, the alkyl or alkylene group is optionally substituted by 1 to 10 R k replace;
[0026] In some embodiments, R 2 Selected from C 1-5 Alkyl or -C 1-4 Alkylene-Q, the alkyl or alkylene group is optionally substituted by 1 to 8 R k replace;
[0027] In some embodiments, R 2 Selected from C 1-4 Alkyl or -C 1-3 Alkylene-Q, the alkyl or alkylene group is optionally substituted by 1 to 6 R k replace;
[0028] In some embodiments, R 2 is selected from methyl, ethyl, propyl, butyl, -methylene-Q, -ethylene-Q, -propylene-Q, wherein the methyl, ethyl, propyl, butyl, methylene, ethylene, butylene are optionally substituted by 1 to 6 R k replace;
[0029] In some embodiments, R 2 Selected from
[0030] In some embodiments, R2 is selected from
[0031] In some embodiments, Q is selected from C 3-12 A carbocyclic group or a 4-12 membered heterocyclic group, wherein the carbocyclic group or the heterocyclic group is optionally substituted by 1 to 4 R q replace;
[0032] In some embodiments, Q is selected from C 3-11 Cycloalkyl, 4- to 11-membered heterocycloalkyl, C 6-10 aryl or 5-10 membered heteroaryl, the cycloalkyl, heterocycloalkyl, aryl, heteroaryl is optionally substituted by 1 to 4 R q replace;
[0033] In some embodiments, Q is selected from C 3-6 Cycloalkyl, 4- to 6-membered heterocycloalkyl, C 6-10 aryl or 5-10 membered heteroaryl, the cycloalkyl, heterocycloalkyl, aryl, heteroaryl is optionally substituted by 1 to 4 R q replace;
[0034] In some embodiments, Q is selected from the group consisting of q Substituted as follows: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, phenyl, pyrrolyl, thienyl, furanyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl;
[0035] In some embodiments, R a , R c , R m , R q , R b3 , R 1a , R 1b , R 1c , R 1d Each independently selected from H, deuterium, halogen, OH, CN, NH2, C 1-6 Alkyl, OC 1-6 Alkyl, SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, -OC 3-6 carbocyclyl, -O-3 to 7 membered heterocyclyl, -NH-C 3-6 carbocyclic group, -NH-3 to 7 membered heterocyclic group, -C 0-4 Alkylene-C 3-6 Carbocyclic group, -C 0-4Alkylene-3 to 7 membered heterocyclic group, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replace;
[0036] In some embodiments, R a , R c , R m , R q , R b3 , R 1a , R 1b , R 1c , R 1d Each independently selected from H, deuterium, halogen, OH, CN, NH2, C 1-4 Alkyl, OC 1-4 Alkyl, SC 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, -OC 3-6 carbocyclic group, -O-3 to 6 membered heterocyclic group, -NH-C 3-6 carbocyclic group, -NH-3 to 6-membered heterocyclic group, -C 0-2 Alkylene-C 3-6 Carbocyclic group, -C 0-2 Alkylene-3 to 6 membered heterocyclic group, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replace;
[0037] In some embodiments, R a , R c , R m , R q , R b3 , R 1a , R 1b , R 1c , R 1d Each independently selected from H, deuterium, F, Cl, Br, I, OH, CN, NH2, NHCH3, N(CH3)2 or optionally substituted by 1 to 4 R k Substituted groups include methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, methylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl, and phenyl;
[0038] In some embodiments, R a , R c , R m , R q , R b3 , R1a , R 1b , R 1c , R 1d Each independently selected from H, deuterium, F, Cl, Br, I, OH, CN, NH2, NHCH3, N(CH3)2 or optionally substituted by 1 to 4 R k substituted methyl, ethyl, methoxy, cyclopropyl;
[0039] In some embodiments, R a , R c , R b3 Each is independently selected from H, deuterium, F, Cl, Br, I, OH, CN, NH2, NHCH3, N(CH3)2, CF3, CHF2, CH2F, methyl, ethyl, methoxy, cyclopropyl;
[0040] In some embodiments, R a or R c Each is independently selected from H, deuterium, F, Cl, Br, I, OH, CN, NH2, NHCH3, N(CH3)2, CF3, CHF2, CH2F, methyl, ethyl, methoxy, cyclopropyl;
[0041] In some embodiments, R 1a With R 1b or R 1c With R 1d Together with the carbon atoms they are connected to form C 3-12 A carbocyclic group or a 4-12 membered heterocyclic group, wherein the carbocyclic group or the heterocyclic group is optionally substituted by 1 to 4 R k replace;
[0042] In some embodiments, R 1a With R 1b or R 1c With R 1d Together with the carbon atoms they are connected to form C 3-11 Cycloalkyl, 4 to 11 membered heterocycloalkyl, the cycloalkyl, heterocycloalkyl is optionally substituted by 1 to 4 R k replace;
[0043] In some embodiments, R 1a With R 1b or R 1c With R 1d Together with the carbon atoms they are connected to form C 3-7 Cycloalkyl, 4 to 7 membered heterocycloalkyl, the cycloalkyl, heterocycloalkyl is optionally substituted by 1 to 4 R k replace;
[0044] In some embodiments, R 1a With R 1bor R 1c With R 1d Each of them and the carbon atom connected thereto together form an optionally substituted 1 to 4 R k Substituted groups include: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl;
[0045] In some embodiments, R b1 , R b2 , R b4 Each independently selected from H, deuterium, OH, CN, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, -NH-C 3-6 carbocyclic group, -NH-3 to 7 membered heterocyclic group, -C 0-4 Alkylene-C 3-6 Carbocyclic group, -C 0-4 Alkylene-3 to 7 membered heterocyclic group, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replace;
[0046] In some embodiments, R b1 , R b2 , R b4 Each independently selected from H, deuterium, OH, CN, NH2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, -NH-C 3-6 carbocyclic group, -NH-3 to 6-membered heterocyclic group, -C 0-2 Alkylene-C 3-6 Carbocyclic group, -C 0-2 Alkylene-3 to 6 membered heterocyclic group, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replace;
[0047] In some embodiments, R b1 , R b2 , R b4 Each independently selected from H, deuterium, OH, CN, NH2 or optionally substituted by 1 to 4 R k Substituted groups: methyl, ethyl, propyl, isopropyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl, phenyl;
[0048] In some embodiments, R b1 , R b2 , R b4 Each independently selected from H, deuterium, OH, CN, NH2, or optionally substituted by 1 to 4 R k substituted methyl, ethyl, methoxy, cyclopropyl;
[0049] In some embodiments, R b1 , R b2 , R b4 Each is independently selected from H, deuterium, OH, CN, NH2, methyl, ethyl, methoxy, cyclopropyl;
[0050] In some embodiments, R k Each independently selected from H, deuterium, halogen, OH, =O, CN, NH2, COOH, CONH2, C 1-6 Alkyl, OC 1-6 Alkyl, SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, -OC 3-6 carbocyclyl, -O-3 to 7 membered heterocyclyl, -NH-C 3-6 carbocyclic group, -NH-3 to 7 membered heterocyclic group, -C 0-4 Alkylene-C 3-6 Carbocyclic group, -C 0-4 Alkylene-3 to 7 membered heterocyclic group, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 groups selected from deuterium, halogen, =O, CN, OH, NH2, C 1-6 Alkyl, C 1-6 substituted by an alkoxy substituent;
[0051] In some embodiments, R k Each independently selected from H, deuterium, halogen, OH, =O, CN, NH2, COOH, CONH2, C 1-4 Alkyl, OC 1-4 Alkyl, SC 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, -OC 3-6 carbocyclic group, -O-3 to 6 membered heterocyclic group, -NH-C 3-6 carbocyclic group, -NH-3 to 6-membered heterocyclic group, -C 0-2 Alkylene-C 3-6Carbocyclic group, -C 0-2 Alkylene-3 to 6 membered heterocyclic group, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 groups selected from deuterium, halogen, =O, CN, OH, NH2, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;
[0052] In some embodiments, R k each independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH2, COOH, CONH2, NHCH3, N(CH3)2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, propargyl, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, phenyl, wherein the methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, propargyl, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, phenyl is optionally substituted by 1 to 4 deuterium, F, Cl, Br, I, =O, CN, OH, NH2, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;
[0053] In some embodiments, R k each independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH2, COOH, CONH2, NHCH3, N(CH3)2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, propargyl, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, phenyl, wherein the methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, propargyl, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, phenyl is optionally substituted with 1 to 4 substituents selected from deuterium, F, Cl, Br, I, =O, CN, OH, NH2, methyl, ethyl, methoxy, ethoxy;
[0054] In some embodiments, a, c, r, and s are each independently selected from 0, 1, 2, 3, and 4.
[0055] In some embodiments, a or c is selected from 0, 1, 2 or 3.
[0056] As a first embodiment of the present invention, the compound represented by the aforementioned general formula (I) or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,
[0057] Z is selected from CH or N;
[0058] A is selected from C 3-12 Carbocyclic group or 4-12 membered heterocyclic group;
[0059] R 1 Selected from -M-(CR 1a R 1b ) r -(CR 1c R 1d ) s -COOH;
[0060] M is selected from a bond, C 3-12 A carbocyclic group or a 4-12 membered heterocyclic group, wherein the carbocyclic group or the heterocyclic group is optionally substituted by 1 to 4 R m replace;
[0061] R 2 Selected from C 1-6 Alkyl or -C 1-6 Alkylene-Q, the alkyl or alkylene group is optionally substituted by 1 to 10 R k replace;
[0062] Q is selected from C 3-12 A carbocyclic group or a 4-12 membered heterocyclic group, wherein the carbocyclic group or the heterocyclic group is optionally substituted by 1 to 4 R q replace;
[0063] R a , R c , R m , R q , R b3 , R 1a , R 1b , R 1c , R 1d Each independently selected from H, deuterium, halogen, OH, CN, NH2, C 1-6 Alkyl, OC 1-6 Alkyl, SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, -OC 3-6 carbocyclyl, -O-3 to 7 membered heterocyclyl, -NH-C 3-6 carbocyclic group, -NH-3 to 7 membered heterocyclic group, -C 0-4 Alkylene-C3-6 Carbocyclic group, -C 0-4 Alkylene-3 to 7 membered heterocyclic group, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replace;
[0064] or R 1a With R 1b or R 1c With R 1d Together with the carbon atoms they are connected to form C 3-12 A carbocyclic group or a 4-12 membered heterocyclic group, wherein the carbocyclic group or the heterocyclic group is optionally substituted by 1 to 4 R k replace;
[0065] R b1 , R b2 , R b4 Each independently selected from H, deuterium, OH, CN, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, -NH-C 3-6 carbocyclic group, -NH-3 to 7 membered heterocyclic group, -C 0-4 Alkylene-C 3-6 Carbocyclic group, -C 0-4 Alkylene-3 to 7 membered heterocyclic group, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replace;
[0066] R k Each independently selected from H, deuterium, halogen, OH, =O, CN, NH2, COOH, CONH2, C 1-6 Alkyl, OC 1-6 Alkyl, SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, -OC 3-6 carbocyclyl, -O-3 to 7 membered heterocyclyl, -NH-C 3-6 carbocyclic group, -NH-3 to 7 membered heterocyclic group, -C 0-4 Alkylene-C 3-6 Carbocyclic group, -C 0-4 Alkylene-3 to 7 membered heterocyclic group, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 groups selected from deuterium, halogen, =O, CN, OH, NH2, C 1-6 Alkyl, C 1-6substituted by an alkoxy substituent;
[0067] a, c, r, s are each independently selected from 0, 1, 2, 3, 4.
[0068] As a second embodiment of the present invention, the compound represented by the aforementioned general formula (I) or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,
[0069] A is selected from C 3-11 Cycloalkyl, 4- to 11-membered heterocycloalkyl, C 6-10 Aryl or 5-10 membered heteroaryl;
[0070] M is selected from a bond, C 3-11 Cycloalkyl, 4- to 11-membered heterocycloalkyl, C 6-10 aryl or 5-10 membered heteroaryl, the cycloalkyl, heterocycloalkyl, aryl, heteroaryl is optionally substituted by 1 to 4 R m replace;
[0071] R 2 Selected from C 1-5 Alkyl or -C 1-4 Alkylene-Q, the alkyl or alkylene group is optionally substituted by 1 to 8 R k replace;
[0072] Q is selected from C 3-11 Cycloalkyl, 4- to 11-membered heterocycloalkyl, C 6-10 aryl or 5-10 membered heteroaryl, the cycloalkyl, heterocycloalkyl, aryl, heteroaryl is optionally substituted by 1 to 4 R q replace;
[0073] R a , R c , R m , R q , R b3 , R 1a , R 1b , R 1c , R 1d Each independently selected from H, deuterium, halogen, OH, CN, NH2, C 1-4 Alkyl, OC 1-4 Alkyl, SC 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, -OC 3-6 carbocyclic group, -O-3 to 6 membered heterocyclic group, -NH-C 3-6 carbocyclic group, -NH-3 to 6-membered heterocyclic group, -C 0-2 Alkylene-C3-6 Carbocyclic group, -C 0-2 Alkylene-3 to 6 membered heterocyclic group, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replace;
[0074] or R 1a With R 1b or R 1c With R 1d Together with the carbon atoms they are connected to form C 3-11 Cycloalkyl, 4 to 11 membered heterocycloalkyl, the cycloalkyl, heterocycloalkyl is optionally substituted by 1 to 4 R k replace;
[0075] R b1 , R b2 , R b4 Each independently selected from H, deuterium, OH, CN, NH2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, -NH-C 3-6 carbocyclic group, -NH-3 to 6-membered heterocyclic group, -C 0-2 Alkylene-C 3-6 Carbocyclic group, -C 0-2 Alkylene-3 to 6 membered heterocyclic group, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replace;
[0076] R k Each independently selected from H, deuterium, halogen, OH, =O, CN, NH2, COOH, CONH2, C 1-4 Alkyl, OC 1-4 Alkyl, SC 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, -OC 3-6 carbocyclic group, -O-3 to 6 membered heterocyclic group, -NH-C 3-6 carbocyclic group, -NH-3 to 6-membered heterocyclic group, -C 0-2 Alkylene-C 3-6 Carbocyclic group, -C 0-2 Alkylene-3 to 6 membered heterocyclic group, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 groups selected from deuterium, halogen, =O, CN, OH, NH2, C 1-4 Alkyl, C 1-4substituted by an alkoxy substituent;
[0077] The remaining definitions are the same as those of the first embodiment of the present invention.
[0078] As a third embodiment of the present invention, the compound represented by the aforementioned general formula (I) or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,
[0079] A is selected from C 3-6 Cycloalkyl, 4- to 6-membered heterocycloalkyl, C 6-10 Aryl or 5-10 membered heteroaryl;
[0080] M is selected from a bond, C 3-6 Cycloalkyl, 4- to 6-membered heterocycloalkyl, C 6-10 aryl or 5-10 membered heteroaryl, the cycloalkyl, heterocycloalkyl, aryl, heteroaryl is optionally substituted by 1 to 4 R m replace;
[0081] R 2 Selected from C 1-4 Alkyl or -C 1-3 Alkylene-Q, the alkyl or alkylene group is optionally substituted by 1 to 6 R k replace;
[0082] Q is selected from C 3-6 Cycloalkyl, 4- to 6-membered heterocycloalkyl, C 6-10 aryl or 5-10 membered heteroaryl, the cycloalkyl, heterocycloalkyl, aryl, heteroaryl is optionally substituted by 1 to 4 R q replace;
[0083] R a , R c , R m , R q , R b3 , R 1a , R 1b , R 1c , R 1d Each independently selected from H, deuterium, F, Cl, Br, I, OH, CN, NH2, NHCH3, N(CH3)2 or optionally substituted by 1 to 4 R k Substituted groups include methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, methylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl, and phenyl;
[0084] or R 1a With R 1b or R 1c With R 1dTogether with the carbon atoms they are connected to form C 3-7 Cycloalkyl, 4 to 7 membered heterocycloalkyl, the cycloalkyl, heterocycloalkyl is optionally substituted by 1 to 4 R k replace;
[0085] R b1 , R b2 , R b4 Each independently selected from H, deuterium, OH, CN, NH2 or optionally substituted by 1 to 4 R k Substituted groups: methyl, ethyl, propyl, isopropyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl, phenyl;
[0086] R k each independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH2, COOH, CONH2, NHCH3, N(CH3)2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, propargyl, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, phenyl, wherein the methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, propargyl, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, phenyl is optionally substituted by 1 to 4 deuterium, F, Cl, Br, I, =O, CN, OH, NH2, C 1-4 Alkyl, C 1-4 substituted by an alkoxy substituent;
[0087] The remaining definitions are the same as those of the first or second embodiment of the present invention.
[0088] As a fourth embodiment of the present invention, the compound represented by the aforementioned general formula (I) or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,
[0089] A is selected from 1 to 4 R a Substituted as follows: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, phenyl, pyrrolyl, thienyl, furanyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl;
[0090] M is selected from a bond or optionally 1 to 4 R mSubstituted groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, phenyl, pyrrolyl, thienyl, furanyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl;
[0091] R 2 is selected from methyl, ethyl, propyl, butyl, -methylene-Q, -ethylene-Q, -propylene-Q, wherein the methyl, ethyl, propyl, butyl, methylene, ethylene, butylene are optionally substituted by 1 to 6 R k replace;
[0092] Q is selected from 1 to 4 R q Substituted as follows: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, phenyl, pyrrolyl, thienyl, furanyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl;
[0093] R a , R c , R m , R q , R b3 , R 1a , R 1b , R 1c , R 1d Each independently selected from H, deuterium, F, Cl, Br, I, OH, CN, NH2, NHCH3, N(CH3)2 or optionally substituted by 1 to 4 R k substituted methyl, ethyl, methoxy, cyclopropyl;
[0094] or R 1a With R 1b or R 1c With R 1d Each of them and the carbon atom connected thereto together form an optionally substituted 1 to 4 R k Substituted groups include: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl;
[0095] R b1 , R b2 , R b4 Each independently selected from H, deuterium, OH, CN, NH2, or optionally substituted by 1 to 4 R k substituted methyl, ethyl, methoxy, cyclopropyl;
[0096] R keach independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH2, COOH, CONH2, NHCH3, N(CH3)2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, propargyl, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, phenyl, wherein the methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, propargyl, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, phenyl is optionally substituted with 1 to 4 substituents selected from deuterium, F, Cl, Br, I, =O, CN, OH, NH2, methyl, ethyl, methoxy, ethoxy;
[0097] The remaining definitions are the same as those of the first, second or third embodiment of the present invention.
[0098] As a fifth embodiment of the present invention, the compound represented by the aforementioned general formula (I) or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal,
[0099] A is selected from 1 to 4 R a Substituted groups include phenyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl, and pyridazinyl;
[0100] R 1 Selected from
[0101] R 2 Selected from
[0102] R a , R c , R b3 Each is independently selected from H, deuterium, F, Cl, Br, I, OH, CN, NH2, NHCH3, N(CH3)2, CF3, CHF2, CH2F, methyl, ethyl, methoxy, cyclopropyl;
[0103] R b1 , R b2 , R b4 Each is independently selected from H, deuterium, OH, CN, NH2, methyl, ethyl, methoxy, cyclopropyl;
[0104] The remaining definitions are the same as those of the first, second, third or fourth embodiment of the present invention.
[0105] As a sixth embodiment of the present invention, the compound represented by the aforementioned general formula (I) or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein the compound represented by the general formula (I) is selected from the compound represented by the general formula (II),
[0106]
[0107] R 1 Selected from
[0108] A is selected from phenyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl;
[0109] R a or R c Each is independently selected from H, deuterium, F, Cl, Br, I, OH, CN, NH2, NHCH3, N(CH3)2, CF3, CHF2, CH2F, methyl, ethyl, methoxy, cyclopropyl;
[0110] a or c is selected from 0, 1, 2 or 3.
[0111] The present invention relates to the following compound or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein the compound is selected from one of the structures in Table E-1 below:
[0112] Table E-1
[0113]
[0114]
[0115]
[0116]
[0117]
[0118]
[0119] The present invention relates to a pharmaceutical composition, comprising the above compound or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, and a pharmaceutically acceptable carrier.
[0120] The present invention relates to the use of the above-mentioned compound or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal or the above-mentioned pharmaceutical composition in preparing a drug for treating diseases associated with sGC.
[0121] The present invention relates to the use of the above-mentioned compound or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal or the above-mentioned pharmaceutical composition in preparing drugs for treating cardiovascular diseases, kidney diseases or respiratory diseases.
[0122] The present invention relates to a pharmaceutical composition or pharmaceutical preparation, which comprises a therapeutically effective amount of the compound of the present invention or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal and a pharmaceutical excipient. The pharmaceutical composition can be in the form of a unit preparation (the amount of the main drug in the unit preparation is also referred to as "preparation specification").
[0123] The present invention also provides a method for treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of the compound of the present invention or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal or pharmaceutical composition. In some embodiments, the mammal of the present invention includes a human.
[0124] "Effective amount" or "therapeutically effective amount" as used herein refers to administering a sufficient amount of the compounds disclosed herein that will alleviate one or more symptoms of the disease or condition (e.g., cardiovascular disease) being treated to some extent. In some embodiments, the result is a reduction and / or alleviation of the signs, symptoms, or causes of the disease, or any other desired change in a biological system. For example, an "effective amount" for therapeutic use is the amount of the compounds disclosed herein required to provide a clinically significant reduction in disease symptoms. Examples of therapeutically effective amounts include, but are not limited to, 0.01-1500 mg, 0.01-1000 mg, 0.01-800 mg, 0.01-600 mg, 0.1-1500 mg, 0.1-1000 mg, 0.1-800 mg, 0.1-600mg、1-1500mg、1-1000mg、1-800mg、1-600mg、2-600mg、3-600mg、4-600mg、5-600mg、6-600mg、10-600mg、20-600mg、25-600mg、30-600mg、40-600mg、50-600mg、60-600mg、70-600mg、75-600mg、80-600mg、90-600mg、100-600mg、200-600mg、1-500mg、2-500mg、3-500mg、4-500mg、5-500mg、6-500mg、10-500mg、20-500mg、25-500mg、30-500mg、40-500mg、50-500mg、60-500mg、70-500mg、75-500mg、80-500mg、90-500mg、100-500mg、125-500mg、150-500mg、200-500mg、250-500mg、300-500mg、400-500mg、5-400mg、10-400mg、20-400mg、25-400mg、30-400mg、40-400mg、50-400mg、60-400mg、70-400mg、75-400mg、80-400mg、90-400mg、100-400mg、125-400mg、150-400mg、200-400mg、250-400mg、300-400mg、1-300mg、2-300mg、5-300mg、10-300mg、20-300mg、25-300mg、30-300mg、40-300mg、50-300mg、60-300mg、70-300mg、75-300mg、80-300mg、90-300mg、100-300mg、125-300mg、150-300mg、200-300mg、250-300mg、1-200mg、2-200mg、5-200mg、10-200mg、20-200mg、25-200mg、30-200mg、40-200mg、50-200mg、60-200mg、70-200mg、75-200mg、80-200mg、90-200mg、100-200mg、125-200mg、150-200mg、0.01-100mg、0.01-50mg、0.01-10mg、0.01-5mg、0.05-10mg、0.05-5mg、0.1-5mg、1-5mg、0.1-1mg、0.1-5mg;.
[0125] In some embodiments, the pharmaceutical composition includes but is not limited to 0.01-1500 mg, 1-1500 mg, 1-1000 mg, 1-800 mg, 1-600 mg, 20-400 mg, 25-200 mg, 0.01 mg, 0.05 mg, 0.1 mg, 0.15 mg, 0.2 mg, 0.3 mg, 0.5 mg, 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg , 65mg, 70mg, 75mg, 80mg, 85mg, 90mg, 95mg, 100mg, 110mg, 120mg, 125mg, 130mg, 140mg, 150mg, 160mg, 170mg, 180mg, 190mg, 200mg, 210mg, 220mg, 230mg, 240mg, 250mg, 300mg of a compound of the present invention or a stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof.
[0126] A method for treating a disease in a mammal, the method comprising administering to a subject a therapeutically effective amount of a compound of the present invention or a stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, the therapeutically effective amount preferably being 0.01-1500 mg, and the disease preferably being a cardiovascular disease.
[0127] A method for treating a disease in a mammal, the method comprising administering to a subject a drug compound of the present invention or a stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof at a daily dose of 0.01-1500 mg / day, the daily dose may be a single dose or divided doses, in some embodiments, the daily dose includes but is not limited to 0.01-1500 mg / day, 10-1500 mg / day, 10-1000 mg / day, 10-800 mg / day, 25-800 mg / day, 50-800 mg / day, 100-800 mg / day, 200-800 mg / day, 2 5-400 mg / day, 50-400 mg / day, 100-400 mg / day, 200-400 mg / day. In some embodiments, daily doses include but are not limited to 0.01 mg / day, 0.05 mg / day, 0.1 mg / day, 0.15 mg / day, 0.2 mg / day, 0.3 mg / day, 0.5 mg / day, 1 mg / day, 2 mg / day, 5 mg / day, 10 mg / day, 20 mg / day, 25 mg / day, 50 mg / day, 100 mg / day, 125 mg / day, 150 mg / day, 200 mg / day, 400 mg / day, 600 mg / day, and 800 mg / day.
[0128] The present invention relates to a kit, which may include a composition in a single-dose or multi-dose form, and the kit contains a compound of the present invention or a stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, and the amount of the compound of the present invention or its stereoisomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal is the same as its amount in the above-mentioned pharmaceutical composition.
[0129] The amount of the compound of the invention or its stereoisomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal in the present invention is in each case calculated as the free base.
[0130] "Preparation specifications" refers to the weight of the main drug contained in each vial, tablet or other unit preparation.
[0131] Synthesis method 1:
[0132]
[0133] R d-11 Selected from C 1-6 alkyl;
[0134] The definitions of the remaining groups are consistent with those described in the present specification;
[0135] The compound of the general formula (D-1-1) is reacted with Lawesson reagent to obtain the compound of the general formula (D-1-2);
[0136] The compound of general formula (D-1-2) is subjected to hydrolysis reaction to obtain the compound of general formula (I).
[0137] Unless stated otherwise, the terms used in this specification and claims have the following meanings.
[0138] The carbon, hydrogen, oxygen, sulfur, nitrogen or F, Cl, Br, I involved in the groups and compounds of the present invention include their isotopes, and the carbon, hydrogen, oxygen, sulfur or nitrogen involved in the groups and compounds of the present invention are optionally replaced by one or more of their corresponding isotopes, wherein the carbon isotopes include 12 C. 13 C and 14 C, hydrogen isotopes include protium (H), deuterium (D, also called heavy hydrogen), tritium (T, also called super tritium), oxygen isotopes include 16 O. 17 O and 18 O, sulfur isotopes include 32 S. 33 S. 34 S and 36 S, isotopes of nitrogen include 14 N and 15 N, fluorine isotopes include 17 F and 19 F, chlorine isotopes include 35 Cl and 37 Isotopes of Cl and bromine include 79 Br and 81 Br.
[0139] "Halogen" refers to F, Cl, Br or I.
[0140] "Halogen substituted" refers to substitution with F, Cl, Br or I, including but not limited to substitution with 1 to 10 substituents selected from F, Cl, Br or I, substitution with 1 to 6 substituents selected from F, Cl, Br or I, substitution with 1 to 4 substituents selected from F, Cl, Br or I. "Halogen substituted" is abbreviated as "halo".
[0141] "Alkyl" refers to a substituted or unsubstituted straight or branched chain saturated aliphatic hydrocarbon group, including but not limited to alkyl groups of 1 to 20 carbon atoms, alkyl groups of 1 to 8 carbon atoms, alkyl groups of 1 to 6 carbon atoms, and alkyl groups of 1 to 4 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, neobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, and various branched chain isomers thereof; the alkyl groups appearing in this article are defined in accordance with this definition. Alkyl groups can be monovalent, divalent, trivalent, or tetravalent.
[0142] "Alkylene" refers to substituted or unsubstituted straight-chain or branched divalent saturated hydrocarbon groups, including -(CH2) v -(v is an integer from 1 to 10), examples of alkylene include but are not limited to methylene, ethylene, propylene and butylene.
[0143] "Cycloalkyl" refers to a substituted or unsubstituted saturated carbocyclic hydrocarbon radical, typically having 3 to 10 carbon atoms, non-limiting examples of which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. Cycloalkyl groups appearing herein are defined as above. Cycloalkyl groups may be monovalent, divalent, trivalent or tetravalent.
[0144] "Heterocycloalkyl" refers to a substituted or unsubstituted saturated cyclic hydrocarbon containing heteroatoms, including but not limited to 3 to 10 atoms, 3 to 8 atoms, including 1 to 3 heteroatoms selected from N, O or S, and the selectively substituted N and S in the ring of heterocycloalkyl can be oxidized to various oxidation states. Heterocycloalkyl can be connected to a heteroatom or a carbon atom, and heterocycloalkyl can be connected to an aromatic ring or a non-aromatic ring. Heterocycloalkyl can be connected to a bridge ring or a spiro ring, and non-limiting examples include oxirane, aziridine, oxadiazine, azetidinyl, tetrahydrofuranyl, tetrahydro-2H-pyranyl, dioxolane, dioxane, pyrrolidinyl, piperidinyl, imidazolidinyl, oxazolidinyl, oxazolidinyl, morpholinyl, hexahydropyrimidinyl, piperazinyl. Heterocycloalkyl can be monovalent, divalent, trivalent or tetravalent.
[0145] "Alkenyl" refers to a substituted or unsubstituted straight chain or branched unsaturated hydrocarbon group having at least one, typically one, two or three carbon-carbon double bonds, with a backbone of 2 to 10, 2 to 6 or 2 to 4 carbon atoms, examples of alkenyl groups include but are not limited to vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 2- Methyl-3-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 1-octenyl, 3-octenyl, 1-nonenyl, 3-nonenyl, 1-decenyl, 4-decenyl, 1,3-butadiene, 1,3-pentadiene, 1,4-pentadiene and 1,4-hexadiene, etc.; the alkenyl groups appearing in this article have the same definition as this definition. The alkenyl group can be monovalent, divalent, trivalent or tetravalent.
[0146] "Alkynyl" refers to substituted or unsubstituted straight and branched unsaturated hydrocarbon groups having at least one, typically one, two or three carbon-carbon triple bonds, with a backbone comprising 2 to 10 carbon atoms, including but not limited to 2 to 6 carbon atoms in the backbone, 2 to 4 carbon atoms in the backbone, examples of alkynyl groups include but are not limited to ethynyl, propargyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 5-pentynyl, 6-pentynyl, 7-pentynyl, 8-pentynyl, 9-pentynyl, 10-pentynyl, 11-pentynyl, 12-pentynyl, 13-pentynyl, 14-pentynyl, 15-pentynyl, 16-pentynyl, 17-pentynyl, 18-pentynyl, 19-pentynyl, 20-pentynyl, 21-pentynyl, 22-pentynyl, 23-pentynyl, 24-pentynyl, 25-pentynyl, 26-pentynyl, 27-pentynyl, 28-pentynyl, 29-pentynyl, 30-pentynyl, 31-pentynyl, 32-pentynyl, 33-pentynyl, 34-pentynyl, 35-pentynyl, 36-pentynyl, 37-pentynyl, 38-pentynyl, 39-pentynyl, 40-pentynyl, 41-pentynyl, 42-pentynyl, 43-pentynyl, 44-pentynyl, 45-pentynyl, 46-pentynyl, 47-pentynyl, 48-pentynyl 1-methyl-1-butynyl, 2-methyl-1-butynyl, 2-methyl-3-butynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-1-pentynyl, 2-methyl-1-pentynyl, 1-heptynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 1-octynyl, 3-octynyl, 1-nonynyl, 3-nonynyl, 1-decynyl, 4-decynyl and the like; the alkynyl group may be monovalent, divalent, trivalent or tetravalent.
[0147] The "propynyl group" means 1-propynyl group and 2-propynyl group.
[0148] "Alkoxy" refers to substituted or unsubstituted -O-alkyl. Non-limiting examples include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, n-hexoxy, cyclopropyloxy, and cyclobutyloxy.
[0149] "Carbocyclyl" or "carbocycle" refers to a substituted or unsubstituted saturated or unsaturated aromatic or non-aromatic ring, which can be a 3-8-membered monocyclic ring, a 4-12-membered bicyclic ring, or a 10-15-membered tricyclic ring system, and the carbocyclyl can be attached to the aromatic or non-aromatic ring, which can be a monocyclic ring, a bridged ring, or a spirocyclic ring. Non-limiting examples include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, 1-cyclopentyl-1-alkenyl, 1-cyclopentyl-2-alkenyl, 1-cyclopentyl-3-alkenyl, cyclohexyl, 1-cyclohexyl-2-alkenyl, 1-cyclohexyl-3-alkenyl, cyclohexenyl, benzene ring, naphthalene ring, "Carbocyclyl" or "carbocycle" can be monovalent, divalent, trivalent or tetravalent.
[0150] "Heterocyclyl" or "heterocycle" refers to a substituted or unsubstituted saturated or unsaturated aromatic or non-aromatic ring, which can be a 3-8 membered monocyclic ring, a 4-12 membered bicyclic ring or a 10-15 membered tricyclic ring system, and contains 1 or more (including but not limited to 2, 3, 4 or 5) heteroatoms selected from N, O or S. The N and S selectively substituted in the heterocyclyl ring can be oxidized to various oxidation states. The heterocyclic group may be connected to a heteroatom or a carbon atom, may be connected to an aromatic ring or a non-aromatic ring, may be connected to a bridged ring or a spiro ring, and non-limiting examples include oxirane, aziridine, oxetanyl, azetidinyl, 1,3-dioxolanyl, 1,4-dioxolanyl, 1,3-dioxhexacyclyl, azepanyl, pyridyl, furanyl, thienyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, piperidinyl, morpholinyl, thiomorpholinyl, 1,3-dithianyl, dihydrofuranyl, dihydropyranyl, dithiolanyl, tetrahydrofuranyl, py ... furanyl, tetrahydropyrrolyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydropyranyl, benzimidazolyl, benzopyridinyl, pyrrolopyridinyl, benzodihydrofuranyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, pyrazinyl, indazolyl, benzothiophenyl, benzofuranyl, benzopyrrolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzopyridinyl, benzopyrimidinyl, benzopyrazinyl, piperazinyl, azabicyclo[3.2.1]octyl, azabicyclo[5.2.0]nonanyl, oxatricyclo[5.3.1.1]dodecyl, azaadamantyl, oxaspiro[3.3]heptanyl, "Heterocyclyl" or "heterocycle" may be monovalent, divalent, trivalent or tetravalent.
[0151] "Spirocycle" or "spirocyclyl" refers to a polycyclic group in which substituted or unsubstituted monocyclic rings share one atom (called spiro atom), and the number of ring atoms in the spirocycle system includes but is not limited to 5 to 20, 6 to 14, 6 to 12, 6 to 10, wherein one or more rings may contain 0 or more (including but not limited to 1, 2, 3 or 4) double bonds, and optionally may contain 1 to 5 selected from N, O or S (=O) n of heteroatoms.
[0152]
[0153] "Spirocycle" or "spirocyclyl" can be monovalent, divalent, trivalent or tetravalent.
[0154] "Parallel ring" or "parallel ring group" refers to a polycyclic group in which each ring in the system shares a pair of adjacent atoms with other rings in the system, wherein one or more rings may contain 0 or more (including but not limited to 1, 2, 3 or 4) double bonds and may be substituted or unsubstituted, and each ring in the parallel ring system may contain 0 to 5 heteroatoms or groups containing heteroatoms (including but not limited to selected from N, S(=O) n or O, n is 0, 1 or 2). The number of ring atoms in the ring system includes, but is not limited to, 5 to 20, 5 to 14, 5 to 12, 5 to 10. Non-limiting examples include: "Bicyclic" or "bicyclic group" can be monovalent, divalent, trivalent or tetravalent.
[0156] "Bridged ring" or "bridged ring group" refers to a substituted or unsubstituted polycyclic group containing two atoms that are not directly connected to any two rings, which may contain 0 or more double bonds, and any ring in the bridged ring system may contain 0 to 5 groups selected from heteroatoms or heteroatom-containing groups (including but not limited to N, S(=O)n or O, where n is 0, 1, 2). The number of ring atoms includes but is not limited to 5 to 20, 5 to 14, 5 to 12 or 5 to 10. Non-limiting examples include Cubane, adamantane. "Bridged ring" or "bridged ring group" can be monovalent, divalent, trivalent or tetravalent.
[0158] "Carbospirocycle", "spirocarbocyclyl", "spirocarbocyclyl" or "carbospirocyclyl" refers to a "spirocycle" whose ring system consists of only carbon atoms. "Carbospirocycle", "spirocarbocyclyl", "spirocarbocyclyl" or "carbospirocyclyl" appearing in this article has the same definition as spirocycle.
[0159] "Carbocyclic ring", "cyclic carbocyclyl", "cyclic carbocyclyl" or "carbocyclic ring" refers to a "cyclic ring" whose ring system consists of only carbon atoms. "Carbocyclic ring", "cyclic carbocyclyl", "cyclic carbocyclyl" or "carbocyclic ring" appearing in this article have the same definition as cyclic ring.
[0160] "Carbobridge ring", "bridged ring carbocyclic group", "bridged carbocyclic group" or "carbon bridged cyclic group" refers to a "bridged ring" whose ring system consists of only carbon atoms. "Carbobridge ring", "bridged ring carbocyclic group", "bridged carbocyclic group" or "carbon bridged cyclic group" appearing in this article have the same definition as the bridged ring.
[0161] "Heteromonocycle", "monocyclic heterocyclyl" or "heteromonocyclic group" refers to a "heterocyclic group" or "heterocycle" of a monocyclic ring system. The heterocyclic group, "monocyclic heterocyclyl" or "heteromonocyclic group" appearing in this document has the same definition as heterocycle.
[0162] "Heterocyclic ring", "heterocyclic ring group", "cyclic heterocyclic group" or "heterocyclic group" refer to a "cyclic ring" containing a heteroatom. The heterocyclic ring, "heterocyclic ring group", "cyclic heterocyclic group" or "heterocyclic group" appearing in this document have the same definition as cyclic ring.
[0163] "Heterospirocycle", "heterospirocyclyl", "spiro heterocyclyl" or "heterospirocyclyl" refers to a "spirocycle" containing a heteroatom. Heterospirocycle, "heterospirocyclyl", "spiro heterocyclyl" or "heterospirocyclyl" appearing herein have the same definition as spirocycle.
[0164] "Heterobridged ring", "heterobridged ring group", "bridged heterocyclic group" or "heterobridged ring group" refers to a "bridged ring" containing a heteroatom. The heterobridged ring, "heterobridged ring group", "bridged heterocyclic group" or "heterobridged ring group" appearing herein have the same definition as the bridged ring.
[0165] "Aryl" or "aromatic ring" refers to a substituted or unsubstituted aromatic hydrocarbon group having a single ring or a fused ring, wherein the number of ring atoms in the aromatic ring includes, but is not limited to, 6 to 18, 6 to 12, or 6 to 10 carbon atoms. The aryl ring may be fused to a saturated or unsaturated carbocyclic or heterocyclic ring, wherein the ring connected to the parent structure is the aryl ring, non-limiting examples of which include benzene ring, naphthalene ring, "Aryl" or "aromatic ring" can be monovalent, divalent, trivalent or tetravalent. When divalent, trivalent or tetravalent, the point of attachment is on the aryl ring.
[0166] "Heteroaryl" or "heteroaromatic ring" refers to a substituted or unsubstituted aromatic hydrocarbon group containing 1 to 5 heteroatoms or groups containing heteroatoms (including but not limited to N, O or S(=O)n, n is 0, 1, 2), and the number of ring atoms in the heteroaromatic ring includes but is not limited to 5 to 15, 5 to 10 or 5 to 6. Non-limiting examples of heteroaryl include but are not limited to pyridyl, furanyl, thienyl, pyridyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, benzopyrazole, benzimidazole, benzopyridine, pyrrolopyridine, etc. The heteroaryl ring can be fused to a saturated or unsaturated carbocyclic ring or heterocyclic ring, wherein the ring connected to the parent structure is a heteroaryl ring, and non-limiting examples include The heteroaryl groups appearing in this article have the same definition as this definition. The heteroaryl group can be monovalent, divalent, trivalent or tetravalent. When divalent, trivalent or tetravalent, the attachment site is located on the heteroaryl ring.
[0167] "Substituted" or "substituted" means substituted by one or more (including but not limited to 2, 3, 4 or 5) substituents, including but not limited to H, F, Cl, Br, I, alkyl, cycloalkyl, alkoxy, haloalkyl, thiol, hydroxyl, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclic, bridged, spiro, cycloalkyl, hydroxyalkyl, =O, carbonyl, aldehyde, carboxylic acid, formate, -(CH2) m -C(=O)-R a 、-O-(CH2) m -C(=O)-R a 、-(CH2) m -C(=O)-NR b R c 、-(CH2) m S(=O) n R a 、-(CH2) m -Alkenyl-R a , OR d or -(CH2) m -alkynyl-R a (wherein m and n are 0, 1 or 2), arylthio, thiocarbonyl, silane or -NR b R c etc., where R b With R c is independently selected from the group consisting of H, hydroxy, amino, carbonyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, sulfonyl, trifluoromethanesulfonyl, and optionally, R b With R c It can form a five- or six-membered cycloalkyl or heterocyclic group. a With R dEach is independently selected from aryl, heteroaryl, alkyl, alkoxy, cycloalkyl, heterocyclyl, carbonyl, ester, bridged, spiro or paracyclic groups.
[0168] “Containing 1 to 5 heteroatoms selected from O, S, and N” means containing 1, 2, 3, 4 or 5 heteroatoms selected from O, S, and N.
[0169] "1 to X substituents selected from..." means substituted by 1, 2, 3...X substituents, where X is selected from any integer between 1 and 10. For example, "1 to 4 R k "Substituted" means replaced by 1, 2, 3 or 4 R k For example, "substituted by 1 to 5 substituents selected from..." means substituted by 1, 2, 3, 4 or 5 substituents selected from..." For example, "the heterobridged ring is optionally substituted by 1 to 4 substituents selected from D or F" means that the heterobridged ring is optionally substituted by 1, 2, 3 or 4 substituents selected from D or F.
[0170] The XY-membered ring (3≤X<Y, Y is any integer between 4 and 12) includes X, X+1, X+2, X+3, X+4...Y-membered rings. The ring includes a heterocyclic ring, a carbocyclic ring, an aromatic ring, an aryl group, a heteroaryl group, a cycloalkyl group, a heteromonocyclic ring, a heterocyclic ring, a heterospirocyclic ring or a heterobridged ring. For example, "a 4-7-membered heteromonocyclic ring" refers to a 4-membered, 5-membered, 6-membered or 7-membered heteromonocyclic ring, and "a 5-10-membered heterocyclic ring" refers to a 5-membered, 6-membered, 7-membered, 8-membered, 9-membered or 10-membered heterocyclic ring.
[0171] "Optional" or "optionally" means that the event or circumstance described later may but need not occur, and the description includes situations where the event or circumstance occurs or does not occur. For example, "alkyl optionally substituted with F" means that alkyl may but need not be substituted with F, and the description includes situations where alkyl is substituted with F and situations where alkyl is not substituted with F.
[0172] "Pharmaceutically acceptable salt" or "pharmaceutically acceptable salt thereof" refers to a salt of the compound of the present invention that retains the biological effectiveness and properties of the free acid or free base, and the free acid is obtained by reacting with a non-toxic inorganic base or organic base, and the free base is obtained by reacting with a non-toxic inorganic acid or organic acid.
[0173] "Pharmaceutical composition" refers to a mixture of one or more compounds of the present invention, or stereoisomers, tautomers, deuterated forms, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or cocrystals thereof and other chemical components, wherein "other chemical components" refers to pharmaceutically acceptable carriers, excipients and / or one or more other therapeutic agents.
[0174] "Carrier" refers to a material that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.
[0175] "Prodrug" refers to a compound of the present invention that can be converted into a biologically active compound through in vivo metabolism. The prodrug of the present invention is prepared by modifying the amino or carboxyl group in the compound of the present invention, and the modification can be removed by conventional operations or in vivo to obtain the parent compound. When the prodrug of the present invention is administered to a mammalian subject, the prodrug is cleaved to form a free amino or carboxyl group.
[0176] "Co-crystal" refers to a crystal formed by the active pharmaceutical ingredient (API) and the co-crystal former (CCF) under the action of hydrogen bonds or other non-covalent bonds, in which the pure state of API and CCF are solid at room temperature and there is a fixed stoichiometric ratio between the components. Co-crystal is a multi-component crystal, including binary eutectics formed between two neutral solids and multi-component eutectics formed between neutral solids and salts or solvates.
[0177] "Animal" is meant to include mammals, such as humans, companion animals, zoo animals, and livestock, preferably humans, horses, or dogs.
[0178] "Stereoisomers" refer to isomers resulting from different spatial arrangements of atoms in a molecule, including cis-trans isomers, enantiomers, diastereomers and conformational isomers.
[0179] "Tautomers" refer to functional group isomers produced by the rapid movement of an atom in a molecule between two positions, such as keto-enol isomerism and amide-imino alcohol isomerism.
[0180] “IC 50 ” is the concentration of a drug or inhibitor required to inhibit a specified biological process (or a component of the process such as an enzyme, receptor, cell, etc.) by half. DETAILED DESCRIPTION
[0181] The following embodiments illustrate the technical solutions of the present invention in detail, but the protection scope of the present invention includes but is not limited to them.
[0182] The structures of the compounds were determined by nuclear magnetic resonance (NMR) or / and mass spectrometry (MS). NMR shifts (δ) were measured in 10 -6 The unit of (ppm) is given. NMR measurements were performed using a (Bruker Avance III 400 and Bruker Avance 300) nuclear magnetic spectrometer, the measurement solvents were deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), deuterated methanol (CD3OD), and the internal standard was tetramethylsilane (TMS);
[0183] MS was measured using (Agilent 6120B (ESI) and Agilent 6120B (APCI));
[0184] HPLC determination was performed using an Agilent 1260DAD high pressure liquid chromatograph (Zorbax SB-C18 100×4.6 mm, 3.5 μM);
[0185] Thin layer chromatography silica gel plate using Yantai Huanghai HSGF 254 or Qingdao GF 254 Silica gel plate: The silica gel plate used in thin layer chromatography (TLC) has a specification of 0.15mm-0.20mm, and the specification used for thin layer chromatography separation and purification of products is 0.4mm-0.5mm;
[0186] Column chromatography generally uses Yantai Huanghai Silica Gel 200-300 mesh silica gel as the carrier;
[0187] Boc: tert-butoxycarbonyl;
[0188] Ts: p-toluenesulfonyl;
[0189] Cbz: benzyloxycarbonyl;
[0190] TMS: trimethylsilyl.
[0191] Example 1: 3-(3-(4-amino-2-(6-chloro-1-(3,3,4,4,4-pentafluorobutyl)-1H-indazol-3-yl)-5-methyl-6-thioxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl)-2,2-dimethylpropanoic acid (Compound 1)
[0192] 3-(3-(4-amino-2-(6-chloro-1-(3,3,4,4,4-pentafluorobutyl)-1H-indazol-3-yl)-5-methyl-6-thioxo-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl)-2,2-dimethylpropanoic acid
[0193]
[0194] Step 1: Preparation of 1A
[0195] Dissolve the compound isobutyryl chloride (7 g, 65.67 mmol) in THF (40 mL), cool to -70 ° C, slowly add potassium tert-butoxide-tetrahydrofuran solution (72 mL, 1N), and naturally warm to room temperature after addition. After stirring for 10 min, add 100 mL of water and 50 mL of methyl tert-butyl ether in sequence, separate the layers, wash the organic layer with saturated brine (50 mL), dry over anhydrous sodium sulfate, and concentrate under reduced pressure. The residue is directly used in the next step.
[0196] Step 2: Preparation of 1B
[0197] Compound 1A (7.77 g, 53.89 mmol) was dissolved in THF (80 mL), replaced with nitrogen three times, cooled to -70 °C, and a tetrahydrofuran solution of LDA (80 mL, 1 N) was slowly added dropwise. After addition, stirring was continued for 30 min, and the temperature was raised to 0 °C and stirred for 10 min. The temperature was lowered to -70 °C, and 20 mL of a tetrahydrofuran solution of 3-iodobenzyl bromide (16 g, 53.89 mmol) was slowly added. After addition, stirring was continued for 1 h. The temperature was naturally raised to room temperature, and 20 mL of a saturated aqueous ammonium chloride solution was added to quench the reaction. 100 mL of water and 100 mL of methyl tert-butyl ether were added and stirred to separate the layers. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate / petroleum ether (V / V) = 0 / 100-5 / 100) to obtain compound 1B (6.3 g, yield: 32%).
[0198] 1 H NMR (400MHz, CDCl3) δ7.56-7.51(m,2H),7.14-7.09(m,1H),7.02–6.95(m,1H),2.75(s,2H),1.45(s,9H),1.13(s,6H).
[0199] Step 3: Preparation of 1C
[0200] Compound 1B (5.8 g, 16.10 mmol) was dissolved in THF (20 mL), replaced with nitrogen three times, cooled to -70 ° C, and slowly added isopropylmagnesium chloride-lithium chloride tetrahydrofuran solution (24 mL, 1N). After addition, the temperature was raised to 0 ° C, stirred for 10 min, cooled to -70 ° C, and diethyl oxalate (3.53 g, 24.15 mmol) was slowly added. After addition, the temperature was naturally raised to room temperature and stirred for 10 min. 10 mL of saturated ammonium chloride aqueous solution was added to quench the reaction, 50 mL of methyl tert-butyl ether and 50 mL of water were added for extraction, the organic layer was washed with saturated brine (50 mL x 1), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate / petroleum ether (V / V) = 0 / 100-8 / 100) to obtain compound 1C (4.2 g, yield: 78%).
[0201] Step 4: 1D preparation
[0202] Compound 1C (2.4 g, 7.18 mmol) was dissolved in a mixed solvent of ethanol (30 mL) and water (1 mL), and malononitrile (1.90 g, 28.79 mmol) and β-alanine (0.064 g, 0.72 mmol) were added in sequence, and stirred at room temperature overnight. The mixture was concentrated under reduced pressure, and the residue was directly purified by column chromatography (ethyl acetate / petroleum ether (V / V) = 0 / 100-10 / 100) to obtain compound 1D (2.56 g, yield: 93%).
[0203] Step 5: Preparation of 1E
[0204] Compound 1D (2.56 g, 6.69 mmol) was dissolved in THF (15 mL), cooled to -70°C under nitrogen protection, and a tetrahydrofuran solution of methylmagnesium chloride (2.7 mL, 3N) was slowly added dropwise. After the addition was completed, stirring was continued for 10 min at this temperature, and 10 ml of 1N aqueous hydrochloric acid was added to quench the reaction. 30 mL of ethyl acetate and 20 mL of water were added for extraction, and the organic phase was washed with saturated brine (20 mL x 1), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate / petroleum ether (V / V) = 0 / 100-10 / 100) to obtain compound 1E (2.13 g, yield: 79%).
[0205] Step 6: Preparation of 1F
[0206] Compound 1E (0.13 g, 0.33 mmol), 6-chloro-1-(3,3,4,4-pentafluorobutyl)-1H-indazole-3-carboxamide (CAS: 1350855-88-7, synthesis reference US20170174693) (0.11 g, 0.33 mmol) and potassium bicarbonate (0.099 g, 0.99 mmol) were mixed and dissolved in tert-butanol (5 mL), heated to 80 ° C and stirred overnight, cooled to room temperature, concentrated under reduced pressure, and the residue was purified by column chromatography (dichloromethane / methanol (V / V) = 100 / 0-100 / 3) to give compound 1F (0.16 g, yield: 70%).
[0207] LCMS m / z=693.3[M+H] +
[0208] Step 7: Preparation of 1G
[0209] Compound 1F (0.10 g, 0.14 mmol) was placed in a microwave tube, and toluene (1 mL) and Lawesson's reagent (0.057 g, 0.14 mmol) were added in sequence. The atmosphere was replaced with nitrogen once, and the reaction was carried out at 115°C for 2 h. The mixture was cooled to room temperature, and 20 mL of ethyl acetate and 20 mL of water were added for extraction. The organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by column chromatography (ethyl acetate / petroleum ether (V / V) = 1 / 5-1 / 1) to obtain compound 1G (50 mg, yield: 50%).
[0210] LCMS m / z=709.2[M+H] +
[0211] Step 8: Preparation of Compound 1
[0212] Compound 1G (0.050 g, 0.071 mmol) was placed in a 50 mL single-necked bottle, trifluoroacetic acid (2 mL) was added, and the mixture was stirred at room temperature for 2 h. The mixture was concentrated under reduced pressure, and the residue was purified by column chromatography (dichloromethane / methanol (V / V) = 100 / 0-100 / 4) to obtain compound 1 (35 mg, yield: 75%).
[0213] LCMS m / z=653.1[M+H] +
[0214] 1 H NMR(400MHz,DMSO-d6)δ13.08(s,1H),12.37–11.89(m,1H),8.72(d,1H),8.04(d,1H),7.32-7.25(m,1H),7.20(t,1H),7.09 –6.98(m,3H),6.77–6.26(m,2H),4.85(t,2H),3.01–2.84(m,2H),2.83–2.67(m,2H),1.85(s,3H),1.05(s,3H),1.00(s,3H).
[0215] Step 9: Compounds 1-1 and 1-2
[0216]
[0217] Compound 1 (30 mg) was used for chiral separation and purification. Preparation conditions: instrument: Waters 150ap; chromatographic column: ChoralPak IC 19*250 5um; column temperature: 35°C; mobile phase: A for CO2, B for methanol (containing 0.05% ammonia water); gradient: B 24%; back pressure: 95 bar; cycle: 3.6 min; detection wavelength: 210 nm; flow rate: 40 ml / min.
[0218] Analysis conditions: instrument: Shimadzu LC-20AD; chromatographic column: CHIRALPAK AD-H 4.6*250mm 5um; mobile phase A: n-hexane, mobile phase B: ethanol; flow rate: 1 ml / min, column temperature: 35°C; detection wavelength: 210 nm; injection volume: 10 μL; running time 20 min; isocratic elution: n-hexane: ethanol = (80:20).
[0219] After preparative separation, fractions with the same retention time were combined and concentrated under reduced pressure to give compound 1-1 (10 mg) and compound 1-2 (10 mg).
[0220] Compound 1-1: Retention time 9.9 min under analytical conditions, LCMS m / z=653.1 [M+H] +
[0221] Compound 1-2: retention time 16.6 min under analytical conditions, LCMS m / z=653.1 [M+H] +
[0222] Example 2: 3-(2-(4-amino-5-methyl-2-(1-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-6-sulfoxy-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-5-yl)thiazol-4-yl)-2,2-dimethylpropanoic acid (Compound 2)
[0223] 3-(2-(4-amino-5-methyl-2-(1-(3,3,4,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-6-thioxo-6,7-dihyd ro-5H-pyrrolo[2,3-d]pyrimidin-5-yl)thiazol-4-yl)-2,2-dimethylpropanoic acid
[0224]
[0225] Step 1: Preparation of 2A
[0226] Compound 1A (3 g, 20.80 mmol) was dissolved in THF (80 mL), replaced with nitrogen three times, cooled to -70 °C, and LDA-tetrahydrofuran solution (27 mL, 1N) was slowly added dropwise. After the addition, stirring was continued for 30 min, the temperature was raised to 0 °C and stirred for 10 min, the temperature was lowered to -70 °C, 2,3-dichloropropylene (2.54 g, 22.88 mmol) was added, stirring was continued for 1 h, the temperature was naturally raised to room temperature, 20 mL of saturated aqueous ammonium chloride solution was added to quench the reaction, 100 mL of water and 100 mL of methyl tert-butyl ether were added, stirred and separated, the organic layer was dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate / petroleum ether (V / V) = 0 / 100-5 / 100) to obtain compound 2A (1.6 g, yield: 40%).
[0227] 1 H NMR (400MHz, CDCl3) δ5.24(d,1H),5.13(d,1H)2.62(s,2H),1.45(s,9H),1.20(s,6H).
[0228] Step 2: Preparation of 2B
[0229] Compound 2A (1.6 g, 7.32 mmol) was dissolved in tert-butyl alcohol (5 mL), water (15 mL) was added, and NBS (1.43 g, 8.05 mmol) was added in batches under ice bath. After the addition, the mixture was naturally heated to room temperature and stirred until dissolved and clear, and the stirring was continued for 30 min. 20 mL of ethyl acetate was added and stirred to separate the layers, and the organic layer was washed with 10 mL of saturated brine, and the organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate / petroleum ether (V / V) = 0 / 10-1 / 10) to obtain compound 2B (0.33 g, yield: 16%).
[0230] 1 H NMR (400MHz, CDCl3) δ3.86(s,2H),2.86(s,2H),1.43(s,9H),1.22(s,6H).
[0231] Step 3: Preparation of 2C
[0232] The compound 4-amino-5-methyl-6-oxo-2-(1-(3,3,4,4-pentafluorobutyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-5-carbothioamide (0.33 g, 0.68 mmol, CAS: 1350854-54-4, synthesized according to patent WO2017197555) and 2B (0.23 g, 0.82 mmol) were mixed and dissolved in ethanol (5 mL), and the temperature was raised to 50 °C and stirred overnight. The mixture was cooled to room temperature, 10 mL of saturated aqueous sodium bicarbonate solution was added and stirred for 10 min, 20 mL of ethyl acetate was added for extraction, the organic layer was washed with 10 mL of saturated brine, the organic layer was taken, dried over sodium sulfate, filtered and concentrated, and the residue was purified by silica gel column chromatography (ethyl acetate / petroleum ether (V / V) = 1 / 10-1 / 1) to give compound 2C (0.36 g, yield: 79%).
[0233] LCMS m / z=665.2[MH] -
[0234] Step 4: 2D preparation
[0235] Compound 2C (0.12 g, 0.18 mmol) was placed in a microwave tube, and toluene (2 mL) and Lawesson's reagent (0.080 g, 0.20 mmol) were added in sequence. The atmosphere was replaced with nitrogen once, and the mixture was reacted at 120°C for 3 h in a microwave oven. The mixture was cooled to room temperature, and 20 mL of ethyl acetate and 20 mL of water were added, stirred, and the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate / petroleum ether (V / V) = 1 / 5-1 / 1) to obtain compound 2D (55 mg, yield 45%).
[0236] LCMS m / z=683.2[M+H] +
[0237] Step 5: Preparation of Compound 2
[0238] Compound 2D (0.055 g, 0.081 mmol) was placed in a 50 mL single-mouth bottle, trifluoroacetic acid (2 mL) was added, and stirred at room temperature for 2 h. The mixture was concentrated under reduced pressure, and the residue was purified by reverse phase flash column (acetonitrile / water (containing 0.1% trifluoroacetic acid) (V / V) = 0 / 100-60 / 40) to obtain trifluoroacetate salt of compound 2 (33 mg).
[0239] LCMS m / z=627.1[M+H] +
[0240] 1H NMR(400MHz,DMSO-d6)δ13.39(s,1H),9.05(dd,1H),8.65(dd,1H),7.40(dd,1H),7.25(s,1H ),7.18–6.88(m,2H),4.90(t,2H),3.06–2.90(m,4H),1.91(s,3H),1.11(s,3H),1.09(s,3H).
[0241] Compounds 2-1 and 2-2
[0242]
[0243] The trifluoroacetate salt of compound 2 (90 mg) was used for chiral separation and purification. The preparation conditions were:
[0244] 1. Instrument: SFC Prep 150AP; Chromatographic column: OJ (19 mm × 250 mm).
[0245] 2. The sample was dissolved in DMF and filtered with a 0.45 μm filter to prepare a sample solution.
[0246] 3. Preparative chromatographic conditions: a. Composition of mobile phase A, B: mobile phase A: CO2, mobile phase B: methanol (containing 0.5% ammonia water); b. Isocratic elution, mobile phase B content 20%; c. Flow rate 41 ml / min.
[0247] After preparative separation, fractions with the same retention time were combined and concentrated under reduced pressure to give compound 2-1 (22 mg) and compound 2-2 (25 mg).
[0248] Compound 2-1: Retention time 4.0 min under preparation conditions, LCMS m / z=626.9 [M+H] +
[0249] 1 H NMR(400MHz,DMSO-d6)δ12.87–11.79(m,1H),9.06(dd,1H),8.65(dd,1H),7.39(dd,1H),7.25(s ,1H),7.14–6.90(m,2H),4.90(t,2H),3.07–2.88(m,4H),1.89(s,3H),1.11(s,3H),1.09(s,3H).
[0250] Compound 2-2: Retention time 4.9 min under preparation conditions, LCMS m / z=627.0 [M+H] +
[0251] Biological test cases
[0252] 1. CHO-KI / sGC cell cGMP detection experiment
[0253] Stable CHO-K1 cells stably expressing sGCα1 / β1 heterodimers were constructed and named CHO-KI / sGC. CHO-KI / sGC cells were cultured in complete medium (FK12+10% FBS+1% double antibody+0.5mg / mL hygromycin+0.25mg / mL G418). On the day of the assay, cells were reselected in EAB assay buffer (EBSS assay buffer+5mL MgCl2+10mM HEPES+0.05% BSA) with a cell concentration of 2.25*10 5 / mL. 0.5 mM IBMX was added to prevent cGMP degradation.
[0254] After the cells were pre-incubated with 1 pM diethylenetriamine / nitric oxide (EDTA-NO) at room temperature for 30 minutes, different concentrations of compounds were added and incubated at 37°C for 1 hour. After the incubation, the reaction was terminated and the intracellular cGMP content was detected according to the instructions of the Cisbio kit (CisBio, 62GM2PEC). The maximum cGMP production relative to the positive compound was calculated according to formula (1), where RLU compound The readout for the detected compound is RLU reference is the maximum reading for positive compounds.
[0255] Activation % = RLU compound / RUL reference *100% Formula (1)
[0256] Conclusion: The compounds of the present invention, such as the compounds in the examples, have a good stimulating effect on the cGMP production of CHO-KI / sGC cells.
[0257] 2. In vitro guanylate cyclase (sGC) enzyme activity assay
[0258] First, 100 nL of compounds of different concentrations were transferred to a 384 reaction plate (Greiner, Cat. No 784075) using Echo655 (LABCYTE, Cat#655), where the DMSO content was 1% at the final reaction concentration; 2 μL sGC (ICE, Cat. NoS2304F-H07SH2) was added to the 384 reaction plate and centrifuged at 1000 rpm for 1 min; then 1 μL DETA NONOate was added and incubated at 37°C for 10 min. After the incubation, 2 μL GTP was added, centrifuged at 1000 rpm for 1 min, and reacted at 37°C for 60 min. In the reaction system, the final concentrations of sGC, GTP, and DETA NONOate were 1.5 nM, 5 μM, and 100 μM, respectively. After the reaction, 5 μL of detection mixture (PerkinElmer, Cat. No62GM2PEG) was added and incubated at room temperature for 60 min. TR-FRET signal (Ratio: 665 / 620 nm) was read using a microplate reader (BMG, Cat. NoPHERAstar FSX). GraphPad Prism software was used to perform nonlinear regression curve fitting and calculate EC 50 Compound A (Example 1 in WO2010065275) was used as a positive reference compound, and the activation rate calculation formula was shown in Formula 2, where Low control was the TR-FRET signal value of 1 μM compound A, and High control was the TR-FRET signal value of the DMSO well.
[0259] stimulation%=(ave High control - cpd well) / (ave High control - aveLow control)*100% Formula 2
[0260] Table 1 Results of test compounds on guanylate cyclase (sGC) enzymatic stimuli and / or activation
[0261] Compound No. <![CDATA[EC 50 (nM)]]> Compound 1-1 A Compound 1-2 A Trifluoroacetate salt of compound 2 A
[0262] Note: A<30nM, 30nM≤B<60nM, 60nM≤C<200nM
[0263] Conclusion: The compounds of the present invention, such as the compounds of the examples, have good agonistic and / or activating effects on the activity of guanylate cyclase (sGC).
[0264] 3. cGMP detection experiment in LNCap cells
[0265] LNCap cells are human prostate cancer cell lines that can express sGC protein. LNCap cells were purchased from ATCC and cultured in complete medium (RPMI-1640+10% FBS+1% PS). On the day of the assay, cells were reselected in assay buffer (EBSSassay buffer+5mL MgCl2+10mM HEPES+0.05% BSA) at a cell concentration of 2*10 5 / mL. 0.5 mM IBMX was added to prevent cGMP degradation.
[0266] The cells were pre-incubated with 20 μM diethylenetriamine / nitric oxide (EDTA-NO) at 37°C for 30 minutes, and then different concentrations of compounds were added and incubated at room temperature for 1 hour. After the incubation, the reaction was terminated and the intracellular cGMP content was detected according to the instructions of the Cisbio kit (CisBio, 62GM2PEC). The cGMP production relative to compound A (Example 1 in WO2010065275) was calculated according to formula (3-1), and EC 50 Sample cGMP is the reading of the test compound, Low control GMP is the 1% DMSO control, and High control cGMP is the reading of compound A at a dose of 10 μM.
[0267] %Activity=(Sample cGMP–Low control GMP) / (High control cGMP-Lowcontrol cGMP)*100% Formula (3-1)
[0268] Table 3-1 Results of the stimulation of cGMP production by test compounds in LNCap cells
[0269] Compound No. <![CDATA[EC 50 (nM)]]> Compound 2-1 <500
[0270] Conclusion: The compounds of the present invention, such as the compounds in the examples, have a good stimulating effect on the cGMP production of LNCap cells.
[0271] 4: Pharmacokinetic test in rats (inhalation administration)
[0272] Experimental purpose: This study administered the test substance to SD rats by single-dose inhalation, determined the concentration of the test substance in rat plasma, and evaluated the pharmacokinetic characteristics and bioavailability of the test substance in rats.
[0273] Experimental animals: Male SD rats, 180-200 g, purchased from Chengdu Dashuo Experimental Animal Co., Ltd.
[0274] Experimental method: On the day of the experiment, SD rats were randomly divided into 6 groups according to body weight, with 2 rats in each group. The rats were fasted but not watered for 12-16 hours one day before administration, and food was resumed 4 hours after administration.
[0275]
[0276] * The dosage is based on the free base; (DMA: dimethylacetamide; HS-15: polyethylene glycol-15-hydroxystearate; Saline: normal saline)
[0277] Plasma sampling: Blood was collected from the eye socket under isoflurane anesthesia before and after administration and placed in an EDTAK2 centrifuge tube. The blood was centrifuged at 6000 rpm and 4°C for 10 min to collect plasma. Plasma collection time points: 0, 0.0833, 0.25, 0.5, 1, 2, 4, 7, 24 h.
[0278] Lung tissue sampling: The experimental animals in each group were euthanized by CO2 inhalation at 0.25, 0.5, 1, 4, 7 and 24 hours after administration. The animals were then dissected, lung tissues were collected, rinsed with physiological saline, wiped dry with filter paper, weighed using a balance, placed on wet ice for 2 hours, and homogenized using 6 times the volume of homogenate (50% methanol-water) (i.e., 1 g of tissue was added to 6 mL of homogenate).
[0279] All samples were stored at -60°C before analysis. The samples were quantitatively analyzed by LC-MS / MS.
[0280] Table 4-1 Pharmacokinetic parameters of test compounds in rats (inhalation administration) Conclusion: The compounds of the present invention, such as the example compounds, have good exposure in the lungs of rats after inhalation administration.
[0281] Test compound <![CDATA[Lung AUC 0-t (h.ng.mL -1 )]]> Compound 2-1 >900
Claims
1. A compound or a stereoisomer, tautomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, the compound being selected from the compounds represented by general formula (I), wherein: Z is selected from CH or N; A is selected from C 3-12 Carbocyclic group or 4-12 membered heterocyclic group; R 1 Selected from -M-(CR 1a R 1b ) r -(CR 1c R 1d ) s -COOH; M is selected from a bond, C 3-12 A carbocyclic group or a 4-12 membered heterocyclic group, wherein the carbocyclic group or the heterocyclic group is optionally substituted by 1 to 4 R m replace; R 2 Selected from C 1-6 Alkyl or -C 1-6 Alkylene-Q, the alkyl or alkylene group is optionally substituted by 1 to 10 R k replace; Q is selected from C 3-12 A carbocyclic group or a 4-12 membered heterocyclic group, wherein the carbocyclic group or the heterocyclic group is optionally substituted by 1 to 4 R q replace; R a , R c , R m , R q , R b3 , R 1a , R 1b , R 1c , R 1d Each independently selected from H, deuterium, halogen, OH, CN, NH2, C 1-6 Alkyl, OC 1-6 Alkyl, SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, -OC 3-6 carbocyclyl, -O-3 to 7 membered heterocyclyl, -NH-C 3-6 carbocyclic group, -NH-3 to 7 membered heterocyclic group, -C 0-4 Alkylene-C 3-6 Carbocyclic group, -C 0-4 Alkylene-3 to 7 membered heterocyclic group, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replace; or R 1a With R 1b or R 1c With R 1d Together with the carbon atoms they are connected to form C 3-12 A carbocyclic group or a 4-12 membered heterocyclic group, wherein the carbocyclic group or the heterocyclic group is optionally substituted by 1 to 4 R k replace; R b1 , R b2 , R b4 Each independently selected from H, deuterium, OH, CN, NH2, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, -NH-C 3-6 carbocyclic group, -NH-3 to 7 membered heterocyclic group, -C 0-4 Alkylene-C 3-6 Carbocyclic group, -C 0-4 Alkylene-3 to 7 membered heterocyclic group, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replace; R k Each independently selected from H, deuterium, halogen, OH, =O, CN, NH2, COOH, CONH2, C 1-6 Alkyl, OC 1-6 Alkyl, SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, NHC 1-6 Alkyl, N(C 1-6 Alkyl)2, -OC 3-6 carbocyclyl, -O-3 to 7 membered heterocyclyl, -NH-C 3-6 carbocyclic group, -NH-3 to 7 membered heterocyclic group, -C 0-4 Alkylene-C 3-6 Carbocyclic group, -C 0-4 Alkylene-3 to 7 membered heterocyclic group, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 groups selected from deuterium, halogen, =O, CN, OH, NH2, C 1-6 Alkyl, C 1-6 substituted by an alkoxy substituent; a, c, r, s are each independently selected from 0, 1, 2, 3, 4.
2. The compound according to claim 1 or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein: A is selected from C 3-11 Cycloalkyl, 4- to 11-membered heterocycloalkyl, C 6-10 Aryl or 5-10 membered heteroaryl; M is selected from a bond, C 3-11 Cycloalkyl, 4- to 11-membered heterocycloalkyl, C 6-10 aryl or 5-10 membered heteroaryl, the cycloalkyl, heterocycloalkyl, aryl, heteroaryl is optionally substituted by 1 to 4 R m replace; R 2 Selected from C 1-5 Alkyl or -C 1-4 Alkylene-Q, the alkyl or alkylene group is optionally substituted by 1 to 8 R k replace; Q is selected from C 3-11 Cycloalkyl, 4- to 11-membered heterocycloalkyl, C 6-10 aryl or 5-10 membered heteroaryl, the cycloalkyl, heterocycloalkyl, aryl, heteroaryl is optionally substituted by 1 to 4 R q replace; R a , R c , R m , R q , R b3 , R 1a , R 1b , R 1c , R 1d Each independently selected from H, deuterium, halogen, OH, CN, NH2, C 1-4 Alkyl, OC 1-4 Alkyl, SC 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, -OC 3-6 carbocyclic group, -O-3 to 6 membered heterocyclic group, -NH-C 3-6 carbocyclic group, -NH-3 to 6-membered heterocyclic group, -C 0-2 Alkylene-C 3-6 Carbocyclic group, -C 0-2 Alkylene-3 to 6 membered heterocyclic group, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replace; or R 1a With R 1b or R 1c With R 1d Together with the carbon atoms they are connected to form C 3-11 Cycloalkyl, 4 to 11 membered heterocycloalkyl, the cycloalkyl, heterocycloalkyl is optionally substituted by 1 to 4 R k replace; R b1 , R b2 , R b4 Each independently selected from H, deuterium, OH, CN, NH2, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, -NH-C 3-6 carbocyclic group, -NH-3 to 6-membered heterocyclic group, -C 0-2 Alkylene-C 3-6 Carbocyclic group, -C 0-2 Alkylene-3 to 6 membered heterocyclic group, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 R k replace; R k Each independently selected from H, deuterium, halogen, OH, =O, CN, NH2, COOH, CONH2, C 1-4 Alkyl, OC 1-4 Alkyl, SC 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, NHC 1-4 Alkyl, N(C 1-4 Alkyl)2, -OC 3-6 carbocyclic group, -O-3 to 6 membered heterocyclic group, -NH-C 3-6 carbocyclic group, -NH-3 to 6-membered heterocyclic group, -C 0-2 Alkylene-C 3-6 Carbocyclic group, -C 0-2 Alkylene-3 to 6 membered heterocyclic group, wherein the alkyl, alkylene, alkenyl, alkynyl, carbocyclic group or heterocyclic group is optionally substituted by 1 to 4 groups selected from deuterium, halogen, =O, CN, OH, NH2, C 1-4 Alkyl, C 1-4 The alkoxy group is substituted with an alkoxy substituent.
3. The compound according to claim 2 or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein: A is selected from C 3-6 Cycloalkyl, 4- to 6-membered heterocycloalkyl, C 6-10 Aryl or 5-10 membered heteroaryl; M is selected from a bond, C 3-6 Cycloalkyl, 4- to 6-membered heterocycloalkyl, C 6-10 aryl or 5-10 membered heteroaryl, the cycloalkyl, heterocycloalkyl, aryl, heteroaryl is optionally substituted by 1 to 4 R m replace; R 2 Selected from C 1-4 Alkyl or -C 1-3 Alkylene-Q, the alkyl or alkylene group is optionally substituted by 1 to 6 R k replace; Q is selected from C 3-6 Cycloalkyl, 4- to 6-membered heterocycloalkyl, C 6-10 aryl or 5-10 membered heteroaryl, the cycloalkyl, heterocycloalkyl, aryl, heteroaryl is optionally substituted by 1 to 4 R q replace; R a , R c , R m , R q , R b3 , R 1a , R 1b , R 1c , R 1d Each independently selected from H, deuterium, F, Cl, Br, I, OH, CN, NH2, NHCH3, N(CH3)2 or optionally substituted by 1 to 4 R k Substituted groups include methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, isopropoxy, vinyl, ethynyl, methylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl, and phenyl; or R 1a With R 1b or R 1c With R 1d Together with the carbon atoms they are connected to form C 3-7 Cycloalkyl, 4 to 7 membered heterocycloalkyl, the cycloalkyl, heterocycloalkyl is optionally substituted by 1 to 4 R k replace; R b1 , R b2 , R b4 Each independently selected from H, deuterium, OH, CN, NH2 or optionally substituted by 1 to 4 R k Substituted groups: methyl, ethyl, propyl, isopropyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, morpholinyl, phenyl; R k each independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH2, COOH, CONH2, NHCH3, N(CH3)2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, propargyl, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, phenyl, wherein the methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, propargyl, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, phenyl is optionally substituted by 1 to 4 deuterium, F, Cl, Br, I, =O, CN, OH, NH2, C 1-4 Alkyl, C 1-4 The alkoxy group is substituted with an alkoxy substituent.
4. The compound according to claim 3 or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein: A is selected from 1 to 4 R a Substituted as follows: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, phenyl, pyrrolyl, thienyl, furanyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl; M is selected from a bond or optionally 1 to 4 R m Substituted groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, phenyl, pyrrolyl, thienyl, furanyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl; R 2 is selected from methyl, ethyl, propyl, butyl, -methylene-Q, -ethylene-Q, -propylene-Q, wherein the methyl, ethyl, propyl, butyl, methylene, ethylene, butylene are optionally substituted by 1 to 6 R k replace; Q is selected from 1 to 4 R q Substituted as follows: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, phenyl, pyrrolyl, thienyl, furanyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl; R a , R c , R m , R q , R b3 , R 1a , R 1b , R 1c , R 1d Each independently selected from H, deuterium, F, Cl, Br, I, OH, CN, NH2, NHCH3, N(CH3)2 or optionally substituted by 1 to 4 R k substituted methyl, ethyl, methoxy, cyclopropyl; or R 1a With R 1b or R 1c With R 1d Each of them and the carbon atom connected thereto together form an optionally substituted 1 to 4 R k Substituted groups include: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl; R b1 , R b2 , R b4 Each independently selected from H, deuterium, OH, CN, NH2, or optionally substituted by 1 to 4 R k substituted methyl, ethyl, methoxy, cyclopropyl; R k each independently selected from deuterium, F, Cl, Br, I, OH, =O, CN, NH2, COOH, CONH2, NHCH3, N(CH3)2, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, propargyl, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, phenyl; the methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, methylthio, vinyl, ethynyl, propynyl, propargyl, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, pyrrolidinyl, piperidinyl, pyrazolyl, pyrrolyl, morpholinyl, phenyl is optionally substituted with 1 to 4 substituents selected from deuterium, F, Cl, Br, I, =O, CN, OH, NH2, methyl, ethyl, methoxy, ethoxy.
5. The compound according to claim 4 or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein: A is selected from 1 to 4 R a Substituted groups include phenyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl, and pyridazinyl; R 1 Selected from R 2 Selected from R a , R c , R b3 Each is independently selected from H, deuterium, F, Cl, Br, I, OH, CN, NH2, NHCH3, N(CH3)2, CF3, CHF2, CH2F, methyl, ethyl, methoxy, cyclopropyl; R b1 , R b2 , R b4 Each is independently selected from H, deuterium, OH, CN, NH2, methyl, ethyl, methoxy, and cyclopropyl.
6. The compound according to claim 1 or its stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal, wherein: The compound represented by general formula (I) is selected from the compounds represented by general formula (II), R 1 Selected from A is selected from phenyl, thiazolyl, oxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl; R a or R c Each is independently selected from H, deuterium, F, Cl, Br, I, OH, CN, NH2, NHCH3, N(CH3)2, CF3, CHF2, CH2F, methyl, ethyl, methoxy, cyclopropyl; a or c is selected from 0, 1, 2 or 3.
7. The compound according to claim 1, or a stereoisomer, tautomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, wherein the compound is selected from one of the structures in Table E-1.
8. A pharmaceutical composition comprising a compound according to any one of claims 1 to 7 or a stereoisomer, tautomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof, and a pharmaceutically acceptable carrier. Preferably, the pharmaceutical composition contains 0.01-1500 mg of a compound according to any one of claims 1 to 7 or a stereoisomer, tautomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal thereof.
9. Use of the compound according to any one of claims 1 to 7 or its stereoisomer, tautomer, deuterated form, solvate, prodrug, metabolite, pharmaceutically acceptable salt or cocrystal or the pharmaceutical composition according to claim 8 in the preparation of a medicament for treating a disease associated with sGC.
10. The use according to claim 9, wherein the disease is selected from cardiovascular disease, kidney disease or respiratory disease.
